Clinically, the IL-33/ST2 pathway is considered a major novel target for therapeutic interventions across a range of diseases, including Alzheimer's disease [54], helminth infections [55], cardiovascular disease [56], obesity [57], asthma [58] and other autoimmune disorders [59], [60]. This evidence concerns the gene IL33 and obesity due to melanocortin 4 receptor deficiency.